Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lisinopril

FDA-approved product (tablet, oral), marketed as Lisinopril, Prinivil, Qbrelis and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Lisinopril
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Congestive heart failure
  • Diabetes mellitus
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Ace inhibitors, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli29.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lisinopril in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lisinopril with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

    NCT07685938 · start 2026-08-12

    Registered record
    Registry ID
    NCT07685938
    Conditions
    Chest Wall Tumor; Breast Cancer; Lung Cancer; Esophageal Cancer; Mediastinal Cancers; Spine Metastases; Spinal Tumor; Thoracic Cancer; Thoracic Neoplasms
    Interventions
    Atorvastatin and Lisinopril; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-08-12
    Completion
    2029-02
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChest Wall Tumor; Breast Cancer; Lung Cancer; Esophageal Cancer +5 more
    InterventionAtorvastatin and Lisinopril; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • The Effect Of Lisinopril On Polycythemia

    NCT07594535 · start 2026-07-01

    Registered record
    Registry ID
    NCT07594535
    Conditions
    Polycythemia
    Interventions
    Lisinopril Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-07-01
    Completion
    2029-07-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycythemia
    InterventionLisinopril Tablets
    PhasePhase 4
    Registry statusRecruiting

  • The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.

    NCT07513883 · start 2026-03-16

    Registered record
    Registry ID
    NCT07513883
    Conditions
    Heart Failure
    Interventions
    Down-titration; Continuation of guideline-directed heart failure therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-03-16
    Completion
    2028-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionDown-titration; Continuation of guideline-directed heart failure therapy
    PhasePhase 4
    Registry statusRecruiting

  • Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

    NCT07568574 · start 2026-03-12

    Registered record
    Registry ID
    NCT07568574
    Conditions
    Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
    Interventions
    Testosterone Enanthate; Testosterone Cypionate; Testosterone Propionate; Sustanon (testosterone); Testosterone Gel; Methenolone Enanthate (Primobolan); Nandrolone Decanoate (Deca-Durabolin); Estradiol Patch; Estradiol Capsule; Progesterone Cream; Progesterone Capsule; Human Growth Hormone (hGH); EPO Darbepoetin (Aranesp); Meldonium; Modafinil; Mixed amphetamine salts (Adderall); Clomiphene; Anastrozole; Levothyroxine; Liothyronine; hCG; hMG; Atorvastatin; Rosuvastatin; Bisoprolol; Nebivolol; Metoprolol; Propranolol; Lisinopril; Enalapril; Furosemide; Chlorothiazide; Cabergoline; Metformin; Basal Insulin Glargine (long-acting); Telmisartan; Losartan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2026-03-12
    Completion
    2033-03-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
    InterventionTestosterone Enanthate; Testosterone Cypionate; Testosterone Propionate; Sustanon (testosterone) +33 more
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • Treatment of Patients With Diabetic Kidney Disease

    NCT06187493 · start 2024-01-01

    Registered record
    Registry ID
    NCT06187493
    Conditions
    Diabetic Kidney Disease
    Interventions
    lisinopril, enalapril; dapagliflozin, empagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-01-01
    Completion
    2025-12-31
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Kidney Disease
    Interventionlisinopril, enalapril; dapagliflozin, empagliflozin
    PhaseNot applicable
    Registry statusUnknown

  • Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

    NCT03502031 · start 2018-10-01

    Registered record
    Registry ID
    NCT03502031
    Conditions
    Renal Insufficiency, Chronic; Diabetic Nephropathy Type 2
    Interventions
    Renin-Angiotensin (RAAS) alone; Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-10-01
    Completion
    2024-10-01
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Insufficiency, Chronic; Diabetic Nephropathy Type 2
    InterventionRenin-Angiotensin (RAAS) alone; Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
    PhasePhase 4
    Registry statusUnknown

  • Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

    NCT03417388 · start 2018-02-09

    Registered record
    Registry ID
    NCT03417388
    Conditions
    Coronary Artery Disease
    Interventions
    High dose potent statin; ACE-I (lisinopril) or ARB (losartan); Aspirin 81 enteric coated tablet daily; Lifestyle Counseling; Quality of Life Questionnaires
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2018-02-09
    Completion
    2026-09-14
    Enrolment
    2,476

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionHigh dose potent statin; ACE-I (lisinopril) or ARB (losartan); Aspirin 81 enteric coated tablet daily; Lifestyle Counseling +1 more
    PhasePhase 4
    Registry statusActive not recruiting

  • Comparison of Optimal Hypertension Regimens

    NCT02847338 · start 2016-11

    Registered record
    Registry ID
    NCT02847338
    Conditions
    Hypertension
    Interventions
    Amlodipine; Lisinopril; Amiloride; Chlortalidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-11
    Completion
    2023-10
    Enrolment
    940

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAmlodipine; Lisinopril; Amiloride; Chlortalidone
    PhasePhase 4
    Registry statusCompleted

  • The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors

    NCT02623036 · start 2015-11

    Registered record
    Registry ID
    NCT02623036
    Conditions
    Hypertension, Resistant to Conventional Therapy
    Interventions
    Equivalent dose enalapril; Equivalent dose lisinopril
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2015-11
    Completion
    2018-04
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Resistant to Conventional Therapy
    InterventionEquivalent dose enalapril; Equivalent dose lisinopril
    PhasePhase 1
    Registry statusUnknown

  • CAndesartan vs LIsinopril Effects on the BRain

    NCT01984164 · start 2014-08-20

    Registered record
    Registry ID
    NCT01984164
    Conditions
    Hypertension; Mild Cognitive Impairment
    Interventions
    Candesartan; Lisinopril
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-08-20
    Completion
    2018-12-03
    Enrolment
    176

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Mild Cognitive Impairment
    InterventionCandesartan; Lisinopril
    PhasePhase 2
    Registry statusCompleted

  • Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

    NCT02232880 · start 2014-08

    Registered record
    Registry ID
    NCT02232880
    Conditions
    Hypertension
    Interventions
    Abatacept; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-08
    Completion
    2015-06
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAbatacept; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients

    NCT02200822 · start 2014-07

    Registered record
    Registry ID
    NCT02200822
    Conditions
    Heart Failure (HF)
    Interventions
    beta blockers; RAAS blockers
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2019-02
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure (HF)
    Interventionbeta blockers; RAAS blockers
    PhasePhase 4
    Registry statusCompleted

  • Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects

    NCT02232308 · start 2014-07

    Registered record
    Registry ID
    NCT02232308
    Conditions
    Gastroparesis
    Interventions
    Nizatidine; Lisinopril; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-07
    Completion
    2014-09
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroparesis
    InterventionNizatidine; Lisinopril; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension

    NCT02184858 · start 2014-06-25

    Registered record
    Registry ID
    NCT02184858
    Conditions
    Primary Hypertension; Secondary Hypertension
    Interventions
    lisinopril, ACE-inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-06-25
    Completion
    2018-09-17
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Hypertension; Secondary Hypertension
    Interventionlisinopril, ACE-inhibitor
    PhasePhase 4
    Registry statusCompleted

  • A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects

    NCT02070510 · start 2014-02-27

    Registered record
    Registry ID
    NCT02070510
    Conditions
    Diabetes; Healthy
    Interventions
    semaglutide; lisinopril; warfarin; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-02-27
    Completion
    2014-08-20
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Healthy
    Interventionsemaglutide; lisinopril; warfarin; placebo
    PhasePhase 1
    Registry statusCompleted